Paola Guglielmelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8047260/publications.pdf

Version: 2024-02-01

343 papers	19,316 citations	13099 68 h-index	12946 131 g-index
357 all docs	357 docs citations	357 times ranked	10072 citing authors

#	Article	IF	Citations
1	SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2. New England Journal of Medicine, 2013, 369, 2391-2405.	27.0	1,556
2	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	1.4	805
3	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
4	Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 2014, 124, 2507-2513.	1.4	575
5	Effect of Mutation Order on Myeloproliferative Neoplasms. New England Journal of Medicine, 2015, 372, 601-612.	27.0	467
6	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. New England Journal of Medicine, 2018, 379, 1416-1430.	27.0	442
7	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 2007, 110, 840-846.	1.4	419
8	The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal, 2018, 8, 15.	6.2	404
9	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	1.6	373
10	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2014, 123, 1552-1555.	1.4	346
11	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	1.4	340
12	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia, 2007, 21, 1952-1959.	7.2	328
13	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
14	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	7.2	300
15	Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia, 2008, 22, 1299-1307.	7.2	273
16	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
17	MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 1769-1770.	1.6	249
18	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 2014, 28, 1494-1500.	7.2	248

#	Article	IF	Citations
19	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	5.2	243
20	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	1.4	242
21	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	7.2	242
22	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19, 1847-1849.	7.2	236
23	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood, 2007, 110, 4030-4036.	1.4	233
24	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	1.4	216
25	Thrombosis in primary myelofibrosis: incidence and risk factors. Blood, 2010, 115, 778-782.	1.4	216
26	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 2018, 32, 1631-1642.	7.2	213
27	A pilot study of the Histoneâ€Ðeacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 2010, 150, 446-455.	2.5	202
28	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	1.4	196
29	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	4.1	176
30	Advances in Understanding and Management of Myeloproliferative Neoplasms. Ca-A Cancer Journal for Clinicians, 2009, 59, 171-191.	329.8	170
31	Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia. Journal of Clinical Oncology, 2008, 26, 2732-2736.	1.6	169
32	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	4.1	165
33	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	3.5	160
34	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	2.5	153
35	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	1.4	153
36	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	3.5	146

#	Article	IF	Citations
37	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	12.8	145
38	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	1.4	144
39	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
40	Mutationâ€enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. British Journal of Haematology, 2020, 189, 291-302.	2.5	134
41	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica, 2016, 101, 926-931.	3.5	118
42	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	1.4	115
43	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	3.2	111
44	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	4.1	107
45	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	1.6	105
46	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	4.1	105
47	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	1.4	105
48	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	1.4	102
49	Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. Journal of Experimental Medicine, 2016, 213, 1479-1496.	8.5	101
50	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	7.2	101
51	Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood, 2008, 112, 3135-3137.	1.4	100
52	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosomeâ€"Negative Myeloproliferative Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2068-2073.	2.5	100
53	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	7.2	96
54	JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood, 2012, 120, 2704-2707.	1.4	94

#	Article	IF	Citations
55	Driver mutations and prognosis in primary myelofibrosis: Mayoâ€Careggi MPN alliance study of 1,095 patients. American Journal of Hematology, 2018, 93, 348-355.	4.1	94
56	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology, 2017, 96, 1653-1665.	1.8	92
57	Hypermethylation ofCXCR4Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. Stem Cells, 2008, 26, 1920-1930.	3.2	91
58	JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera. Experimental Hematology, 2009, 37, 1016-1021.	0.4	89
59	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	1.4	83
60	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	2.5	82
61	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer Journal, 2016, 6, e493-e493.	6.2	80
62	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
63	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. PLoS ONE, 2013, 8, e54826.	2.5	80
64	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	1.4	79
65	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq1 1 0.784314 rgBT /Overloc	4.6	79
66	Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. American Journal of Hematology, 2014, 89, 588-590.	4.1	75
67	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia, 2014, 28, 1811-1818.	7.2	75
68	Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer Journal, 2015, 5, e360-e360.	6.2	72
69	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.4	71
70	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	7.2	70
71	A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20, 1055-1060.	7.2	68
72	Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Annals of Hematology, 2017, 96, 1113-1120.	1.8	68

#	Article	IF	Citations
73	Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Advances, 2018, 2, 2964-2972.	5.2	68
74	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia, 2019, 33, 1996-2005.	7.2	67
75	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	7.2	66
76	Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. British Journal of Haematology, 2005, 130, 271-275.	2.5	63
77	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. American Journal of Pathology, 2005, 167, 849-858.	3.8	62
78	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia, 2021, 35, 1121-1133.	7.2	61
79	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules, and Diseases, 2007, 38, 280-286.	1.4	60
80	Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia, 2011, 25, 1834-1839.	7.2	59
81	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica, 2009, 94, 1537-1545.	3.5	58
82	Ruxolitinibâ€induced reversal of alopecia universalis in a patient with essential thrombocythemia. American Journal of Hematology, 2015, 90, 82-83.	4.1	56
83	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 2018, 97, 1591-1600.	1.8	53
84	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	4.1	53
85	The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia, 2006, 20, 2074-2076.	7.2	51
86	Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia, 2013, 27, 2084-2086.	7.2	51
87	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	5.2	51
88	Insights into JAK2-V617F mutation in CML. Lancet Oncology, The, 2007, 8, 864-866.	10.7	50
89	Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2010, 85, 97-100.	4.1	48
90	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	2.8	47

#	Article	IF	Citations
91	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
92	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	1.4	47
93	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer Journal, 2021, 11, 199.	6.2	47
94	FLT3-Mediated p38â€“MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. Cancer Research, 2011, 71, 2901-2915.	0.9	46
95	Venetoclax with azacitidine or decitabine in blastâ€phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	4.1	46
96	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
97	Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S307-S309.	0.4	45
98	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 2010, 95, 1435-1438.	3.5	41
99	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	1.4	41
100	Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of Hematology and Oncology, 2017, 10, 54.	17.0	41
101	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
102	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	7.2	41
103	JAK2 Mutation-Related Disease and Thrombosis. Seminars in Thrombosis and Hemostasis, 2013, 39, 496-506.	2.7	40
104	Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology, 2010, 89, 141-146.	1.8	39
105	Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data . OncoTargets and Therapy, 2020, Volume 13, 12367-12382.	2.0	39
106	A lifeâ€threatening ruxolitinib discontinuation syndrome. American Journal of Hematology, 2017, 92, 833-838.	4.1	38
107	Ruxolitinib is an effective treatment for <scp>CALR</scp>â€positive patients with myelofibrosis. British Journal of Haematology, 2016, 173, 938-940.	2.5	36
108	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica, 2009, 94, 144-146.	3.5	35

#	Article	IF	Citations
109	Current management strategies for polycythemia vera and essential thrombocythemia. Blood Reviews, 2020, 42, 100714.	5.7	35
110	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 21.	6.2	35
111	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	1.4	34
112	CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. American Journal of Hematology, 2014, 89, 453-456.	4.1	34
113	Second cancers in MPN: Survival analysis from an international study. American Journal of Hematology, 2020, 95, 295-301.	4.1	34
114	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood, 2020, 135, 287-292.	1.4	34
115	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	5.2	34
116	JAK inhibitors and COVID-19. , 2022, 10, e002838.		34
117	Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation inJAK2V617Fmutated cells through PP2A/CIP2A axis. Oncotarget, 2017, 8, 96710-96724.	1.8	32
118	CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia, 2015, 29, 1209-1210.	7.2	31
119	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31
120	Myelofibrosis Treatment Algorithm 2018. Blood Cancer Journal, 2018, 8, 72.	6.2	31
121	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	3.3	31
122	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer Journal, 2022, 12, 28.	6.2	31
123	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	2.5	30
124	Impaired response to first <scp>SARSâ€CoV</scp>â€2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. American Journal of Hematology, 2021, 96, E408-E410.	4.1	30
125	A Phase 2A study of the Histone-Deacetylase Inhibitor ITF2357 in Patients with Jak2V617F Positive Chronic Myeloproliferative Neoplasms. Blood, 2008, 112, 100-100.	1.4	28
126	Gender and survival in essential thrombocythemia: A twoâ€center study of 1,494 patients. American Journal of Hematology, 2017, 92, 1193-1197.	4.1	27

#	Article	IF	Citations
127	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	6.2	27
128	JAK2 exon 12 mutated polycythemia vera: Mayoâ€Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. American Journal of Hematology, 2018, 93, E93-E96.	4.1	27
129	Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis. Haematologica, 2019, 104, e551-e554.	3.5	27
130	Integration of Mutations and Karyotype Towards a Genetics-Based Prognostic Scoring System (GPSS) for Primary Myelofibrosis. Blood, 2014, 124, 406-406.	1.4	27
131	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica, 2007, 92, 258-259.	3.5	26
132	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood, 2011, 117, 6923-6927.	1.4	26
133	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	6.2	26
134	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia, 2018, 32, 438-449.	7.2	26
135	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer Journal, 2021, 11, 21.	6.2	26
136	Mutations and thrombosis in essential thrombocythemia. Blood Cancer Journal, 2021, 11, 77.	6.2	26
137	Differential Amplification of Murine Bipotent Megakaryocytic/Erythroid Progenitor and Precursor Cells During Recovery from Acute and Chronic Erythroid Stress. Stem Cells, 2006, 24, 337-348.	3.2	25
138	Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica, 2008, 93, 972-976.	3.5	25
139	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.8	25
140	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer Journal, 2018, 8, 122.	6.2	25
141	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica, 2013, 98, e101-e102.	3.5	24
142	Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine, 2009, 13, 1437-1450.	3.6	23
143	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 2018, 97, 617-627.	1.8	23
144	Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2007, 40, 1001-1002.	2.4	22

#	Article	IF	Citations
145	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	7.2	22
146	PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology, 2004, 127, 214-219.	2.5	21
147	Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. PLoS ONE, 2015, 10, e0140445.	2.5	20
148	Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients. American Journal of Hematology, 2021, 96, 1472-1480.	4.1	20
149	ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood Advances, 2022, 6, 2927-2931.	5.2	20
150	Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica, 2010, 95, 2153-2156.	3.5	19
151	Role of TGF â€β21/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	4.6	19
152	CircRNAs Are Here to Stay: A Perspective on the MLL Recombinome. Frontiers in Genetics, 2019, 10, 88.	2.3	19
153	A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 100.	6.2	19
154	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leukemia and Lymphoma, 2021, 62, 918-926.	1.3	19
155	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. Blood, 2012, 120, 431-431.	1.4	19
156	Phase I/II study of singleâ€agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology, 2010, 85, 616-619.	4.1	18
157	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers, 2020, 12, 1746.	3.7	18
158	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. Blood, 2020, 135, 381-386.	1.4	18
159	Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2022, 97, E35.	4.1	18
160	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. Leukemia Research, 2008, 32, 516-517.	0.8	17
161	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	2.1	17
162	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	7.2	17

#	Article	IF	Citations
163	CXCR4â€independent rescue of the myeloproliferative defect of the gata1^{low} myelofibrosis mouse model by AplidinÂ®. Journal of Cellular Physiology, 2010, 225, 490-499.	4.1	16
164	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	6.2	16
165	What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?. Hematology American Society of Hematology Education Program, 2017, 2017, 480-488.	2.5	16
166	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
167	The prognostic impact of bone marrow fibrosis in primary myelofibrosis. American Journal of Hematology, 2016, 91, E454-5.	4.1	15
168	Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Bioinformatics, 2019, 35, 4213-4221.	4.1	15
169	The Clinical Phenotype of Patients with Essential Thrombocythemia Harboring MPL 515W>L/K Mutation.. Blood, 2007, 110, 678-678.	1.4	15
170	Risk of second cancers in chronic myeloproliferative neoplasms. Blood, 2012, 119, 3861-3862.	1.4	14
171	Abnormal expression patterns ofWT1-as, MEG3andANRILlong non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	1.3	14
172	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	4.1	14
173	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. Blood, 2006, 108, 5-5.	1.4	14
174	RAD001, An Inhibitor of mTOR, Shows Clinical Activity in a Phase I/II Study in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (PPV/PET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	14
175	Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus. Leukemia, 2015, 29, 2069-2074.	7.2	13
176	Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms. American Journal of Hematology, 2016, 91, E356.	4.1	13
177	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	1.8	13
178	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
179	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	6.2	13
180	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology, 2020, 99, 65-72.	1.8	13

#	Article	IF	Citations
181	Cerebral venous thrombosis and myeloproliferative neoplasms: A threeâ€center study of 74 consecutive cases. American Journal of Hematology, 2021, 96, 1580-1586.	4.1	13
182	Polycythemia vera and essential thrombocythemia: algorithmic approach. Current Opinion in Hematology, 2018, 25, 112-119.	2.5	12
183	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	1.4	12
184	Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. International Journal of Molecular Sciences, 2020, 21, 3900.	4.1	12
185	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	6.2	12
186	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	5.2	12
187	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. British Journal of Haematology, 2006, 132, 652-654.	2.5	11
188	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. Blood, 2007, 110, 4620-4621.	1.4	11
189	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leukemia Research, 2015, 39, 314-317.	0.8	11
190	STAT1 activation in association with JAK2 exon 12 mutations. Haematologica, 2016, 101, e15-e19.	3.5	11
191	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	1.7	11
192	Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells, 2021, 10, 1962.	4.1	11
193	Genetic lesions disrupting calreticulin 3â€²â€untranslated region in <scp>JAK2</scp> mutationâ€negative polycythemia <scp>vera</scp>. American Journal of Hematology, 2020, 95, E263.	4.1	9
194	Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer Journal, 2021, 11, 115.	6.2	9
195	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	3.7	9
196	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. Blood, 2014, 124, 1824-1824.	1.4	9
197	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	2.5	9
198	Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American Journal of Hematology, 2022, 97, 846-855.	4.1	9

#	Article	IF	Citations
199	SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. American Journal of Hematology, 2022, 97, .	4.1	9
200	Advances in understanding and management of polycythemia vera. Current Opinion in Oncology, 2010, 22, 636-641.	2.4	8
201	Struggling with myelofibrosis-associated anemia. Leukemia Research, 2013, 37, 1429-1431.	0.8	8
202	Traffic lights for ruxolitinib. Blood, 2017, 130, 1075-1077.	1.4	8
203	The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells. American Journal of Hematology, 2018, 93, 615-622.	4.1	8
204	Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E23-E26.	4.1	8
205	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	4.1	8
206	The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVIDâ€19. International Journal of Laboratory Hematology, 2020, 42, e270-e273.	1.3	8
207	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
208	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 2914-2914.	1.4	8
209	No role for CXCL12â€“G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. Leukemia, 2008, 22, 669-671.	7.2	7
210	Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms. Expert Review of Hematology, 2014, 7, 423-425.	2.2	7
211	Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial. Blood Cancer Journal, 2015, 5, e286-e286.	6.2	7
212	A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. Blood, 2010, 116, 314-314.	1.4	7
213	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,. Blood, 2011, 118, 3835-3835.	1.4	7
214	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	7.2	7
215	Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology, 2009, 2, 41-55.	2.2	6
216	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	5.1	6

#	Article	IF	Citations
217	Validation of the Mayo alliance prognostic system for mastocytosis. Blood Cancer Journal, 2019, 9, 18.	6.2	6
218	An agenda for future research projects in polycythemia vera and essential thrombocythemia. Haematologica, 2020, 105, 1999-2003.	3.5	6
219	Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. Leukemia and Lymphoma, 2020, 61, 1535-1547.	1.3	6
220	The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 Ã— 109/L to < 100 Ã— 109/L) at Baseline. Blood, 2020, 136, 4-5.	1.4	6
221	Aplidin Improves Megakaryocytopoiesis and Halts Neo-Angiogenesis in the Gata1low Murine Model of Myelofibrosis. Blood, 2008, 112, 2787-2787.	1.4	6
222	A Myelodepletive Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis. Blood, 2021, 138, 1498-1498.	1.4	6
223	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	5.1	6
224	Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis. Genomics Data, 2015, 5, 1-2.	1.3	5
225	Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis. American Journal of Hematology, 2019, 94, 845-852.	4.1	5
226	Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 615-628.	3.4	5
227	Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature. Clinical and Experimental Medicine, 2020, 20, 313-320.	3.6	5
228	Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). Blood, 2018, 132, 578-578.	1.4	5
229	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	1.4	5
230	The MPL mutation. International Review of Cell and Molecular Biology, 2021, 365, 163-178.	3.2	5
231	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	2.4	4
232	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	2.5	4
233	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 523-524.	1.8	4
234	Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clinical Chemistry, 2019, 65, 1605-1608.	3.2	4

#	Article	IF	Citations
235	Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis. Frontiers in Oncology, 2020, 10, 584541.	2.8	4
236	Stem cell transplant for the treatment of myelofibrosis. Expert Review of Hematology, 2020, 13, 363-374.	2.2	4
237	Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). Blood, 2019, 134, 2968-2968.	1.4	4
238	LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis. Blood, 2010, 116, 4105-4105.	1.4	4
239	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. Blood, 2011, 118, 2811-2811.	1.4	4
240	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. Blood, 2013, 122, 1583-1583.	1.4	4
241	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). Blood, 2014, 124, 1826-1826.	1.4	4
242	A JAK2V617F Variant Allele Frequency Greater Than 50% Identifies Patients with Polycythemia Vera at High Risk for Venous Thrombosis. Blood, 2021, 138, 237-237.	1.4	4
243	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. Liver International, 2022, 42, 419-424.	3.9	4
244	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. British Journal of Haematology, 2018, 182, 279-284.	2.5	3
245	Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases. Hematological Oncology, 2019, 37, 628-633.	1.7	3
246	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology, 2019, 94, E239-E242.	4.1	3
247	The JAK2 46/1 (GGCC) MPNâ€predisposing haplotype: A risky haplotype, after all. American Journal of Hematology, 2019, 94, 283-285.	4.1	3
248	Lenalidomide: A doubleâ€edged sword for concomitant multiple myeloma and postâ€essential thrombocythemia myelofibrosis. American Journal of Hematology, 2021, 96, 749-754.	4.1	3
249	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia and Lymphoma, 2022, 63, 189-198.	1.3	3
250	Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study. Blood, 2018, 132, 1754-1754.	1.4	3
251	Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM).. Blood, 2005, 106, 258-258.	1.4	3
252	Constitutively Activated and Hyper-Sensitive Basophils in Patients with Polycythemia Vera: Role of JAK2V617F Mutation and Correlation with Pruritus. Blood, 2008, 112, 3714-3714.	1.4	3

#	Article	IF	Citations
253	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	1.4	3
254	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS ONE, 2016, 11, e0156990.	2.5	3
255	Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Medicine Reports, 2010, 2, .	2.9	3
256	Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. Blood, 2013, 122, 1587-1587.	1.4	3
257	Pregnancy in patients with myelofibrosis: Mayoâ€“Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	2.5	2
258	PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT. HemaSphere, 2019, 3, 671.	2.7	2
259	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. Blood, 2019, 134, 4170-4170.	1.4	2
260	Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera. Blood, 2008, 112, 179-179.	1.4	2
261	High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly.. Blood, 2009, 114, 309-309.	1.4	2
262	Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study. Blood, 2011, 118, 2812-2812.	1.4	2
263	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	1.4	2
264	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. Blood, 2015, 126, 1602-1602.	1.4	2
265	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. Blood, 2015, 126, 2803-2803.	1.4	2
266	Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study. Blood, 2015, 126, 4087-4087.	1.4	2
267	Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes. Blood, 2015, 126, 4091-4091.	1.4	2
268	The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis. Blood, 2021, 138, 236-236.	1.4	2
269	A Globally Applicable "Triple AAA" Risk Model for Essential Thrombocythemia Based on Age, Absolute Neutrophil Count, and Absolute Lymphocyte Count. Blood, 2021, 138, 238-238.	1.4	2
270	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	2.2	2

#	Article	IF	Citations
271	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. Clinical Leukemia, 2007, 1, 339-344.	0.2	1
272	Animal Models of Myelofibrosis. , 2008, , 713-723.		1
273	JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss. Thrombosis Research, 2009, 124, 377-378.	1.7	1
274	Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs, 2014, 2, 841-850.	0.8	1
275	What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?. Current Hematologic Malignancy Reports, 2015, 10, 380-387.	2.3	1
276	A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease. American Journal of Hematology, 2020, 95, 1622-1624.	4.1	1
277	Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. Blood, 2018, 132, 3040-3040.	1.4	1
278	Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 4279-4279.	1.4	1
279	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	1.4	1
280	Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics. Blood, 2019, 134, 1668-1668.	1.4	1
281	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. Blood, 2009, 114, 2915-2915.	1.4	1
282	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	1.4	1
283	Interlaboratory Quality Control Round of MPL Mutation Detection in Fourteen European Laboratories: A MPN&MPNr-EuroNet Study,. Blood, 2011, 118, 3859-3859.	1.4	1
284	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. Blood, 2013, 122, 1582-1582.	1.4	1
285	The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients. Blood, 2013, 122, LBA-2-LBA-2.	1.4	1
286	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	1.4	1
287	A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group. Blood, 2014, 124, 3192-3192.	1.4	1
288	Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. Blood, 2015, 126, 2801-2801.	1.4	1

#	Article	IF	Citations
289	Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients. Blood, 2015, 126, 351-351.	1.4	1
290	Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group. Blood, 2016, 128, 943-943.	1.4	1
291	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. Blood, 2019, 134, 4179-4179.	1.4	1
292	Neutrophil-to-Lymphocyte Ratio (NLR) Is a Risk Factor for Venous Thrombosis in Polycythemia Vera. Blood, 2021, 138, 1499-1499.	1.4	1
293	Screening for Hereditary Alpha-Tryptasemia in Subjects with Systemic Mastocytosis (SM) and Non-SM Mast Cell Activation Symptoms. Blood, 2021, 138, 1500-1500.	1.4	1
294	Deciphering the Individual Contribution of Absolute Neutrophil, Lymphocyte and Monocyte Counts to Thrombosis Risk in Patients with Myeloproliferative Neoplasms. Blood, 2021, 138, 3651-3651.	1.4	1
295	Mutation Landscape and Prognostic Correlates of ASXL1 Variants in Primary and Secondary Myelofibrosis. Blood, 2021, 138, 2578-2578.	1.4	1
296	Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms. Blood, 2021, 138, 56-56.	1.4	1
297	Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRÎ±, PDGFRÎ², FGFR1 or PCM1-JAK2. Biomarker Research, 2021, 9, 83.	6.8	1
298	Concomitant <scp>JAK2</scp> mutated myeloproliferative neoplasms and hereditary hemochromatosis. International Journal of Laboratory Hematology, 2022, 44, 999-1000.	1.3	1
299	The newly diagnosed patient with polycythemia vera. , 0, , 64-69.		0
300	Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S354-S355.	0.4	0
301	Clonal architecture of JAK2<scp>V617F</scp> mutated cells during treatment with ruxolitinib. Hematological Oncology, 2018, 36, 357-359.	1.7	0
302	BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Tumori, 2021, 107, NP28-NP32.	1.1	0
303	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance â€“ÂMYNERVA-GIMEMA AML1919 trial. Future Oncology, 2021, 17, 3787-3796.	2.4	0
304	Splenectomy Favours Development of Extramedullary Hematopoiesis in the GATA-1low Model of Myelofibrosis.. Blood, 2005, 106, 3513-3513.	1.4	0
305	Hypermethylation of CXCR4 Promoter, and Its Reactivation by Hypomethylating Agent, in CD34+ Cells from Primary Myelofibrosis Patients. Blood, 2007, 110, 1545-1545.	1.4	0
306	Clinical Relevance of JAK2V617F Allele Burden in Primary and Post-Polycythemic/Post-Thrombocythemic Myelofibrosis. Blood, 2008, 112, 2799-2799.	1.4	0

#	Article	IF	Citations
307	Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden.. Blood, 2008, 112, 1745-1745.	1.4	0
308	Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients.. Blood, 2009, 114, 1892-1892.	1.4	0
309	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. Blood, 2009, 114, 3891-3891.	1.4	0
310	Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.. Blood, 2009, 114, 3907-3907.	1.4	0
311	Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera.. Blood, 2009, 114, 3896-3896.	1.4	0
312	Characterization of Targets of Plitidepsin In JAK2V617F-Mutated Cells From Myeloproliferative Neoplasms. Blood, 2010, 116, 4093-4093.	1.4	0
313	C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,. Blood, 2011, 118, 3386-3386.	1.4	0
314	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	1.4	0
315	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	1.4	0
316	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	1.4	0
317	Somatic and Germ-Line Molecular Characteristics Of Prefibrotic Myelofibrosis. Blood, 2013, 122, 4058-4058.	1.4	0
318	JAK2V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib. Blood, 2014, 124, 3185-3185.	1.4	0
319	Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group. Blood, 2014, 124, 3179-3179.	1.4	0
320	Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia. Blood, 2014, 124, 404-404.	1.4	0
321	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. Blood, 2014, 124, 1867-1867.	1.4	0
322	A Retrospective Analysis of Safety and Efficacy of Ruxolitinib in CALR-Positive Patients with Myelofibrosis. Blood, 2014, 124, 1853-1853.	1.4	0
323	A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis. Blood, 2015, 126, 1627-1627.	1.4	0
324	JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment. Blood, 2015, 126, 1630-1630.	1.4	0

#	Article	IF	Citations
325	Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors. Blood, 2015, 126, 353-353.	1.4	0
326	IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers. Blood, 2015, 126, 1615-1615.	1.4	0
327	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	1.4	0
328	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	1.4	0
329	The Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Quality of Life and Productivity: Results from the International MPN Landmark Survey. Blood, 2016, 128, 4267-4267.	1.4	0
330	Prognotic Impact of Mutations in Systemic Mastocytosis. Blood, 2016, 128, 1953-1953.	1.4	0
331	JAK2V617F Variant Allele Frequency Identifies Patients with Polycythemia Vera (PV) at High Risk for Venous Thrombosis. Blood, 2018, 132, 1776-1776.	1.4	0
332	Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 1777-1777.	1.4	0
333	Large Genomic Alterations Occurring in the Transition from Chronic to Blast Phase of Chronic Myeloproliferative Neoplasms. Blood, 2018, 132, 3028-3028.	1.4	0
334	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). Blood, 2018, 132, 4312-4312.	1.4	0
335	Absence of Calreticulin Phenocopies Cellular Abnormalities Induced By Calreticulin Exon-9 Mutation in Myeloproliferative Neoplasms. Blood, 2018, 132, 1780-1780.	1.4	0
336	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	1.4	0
337	Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis. Blood, 2019, 134, 1657-1657.	1.4	0
338	Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study. Blood, 2019, 134, 1662-1662.	1.4	0
339	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	1.4	0
340	Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN). Blood, 2019, 134, 471-471.	1.4	0
341	Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis. Blood, 2019, 134, 4209-4209.	1.4	0
342	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	1.4	0

#	Article	IF	Citations
343	Second Versus First Wave of COVID-19 in Patients with MPN. Blood, 2021, 138, 315-315.	1.4	0